A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

Michael A. Morse(Duke Medical Center), H. Kim Lyerly(Duke Medical Center), E. Kitrell-Fisher, Smita K. Nair(Duke University), Jeffrey Schlom(National Cancer Institute), Shelley Hull, Yuping Deng, D Coleman, Mary Ellen Ryback

PubMed

June 1, 1999

Cited by 300

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

|The Lancet Oncology|2017|2.8k

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

|The Journal of Experimental Medicine|2006|1.7k

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

|Journal of Clinical Oncology|2010|973

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

|Blood|2005|896

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

|Journal of the National Comprehensive Cancer Network|2007|636